TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2719.
Locate Jan Aushadhi KendraClinical Overview
Olaparib Tablets (100mg, 150mg) is a first-in-class oral poly(ADP-ribose) polymerase (PARP-1, PARP-2, PARP-3) inhibitor on the WHO Model List of Essential Medicines. It traps inactivated PARP enzymes at single-strand DNA breaks, transforming them into lethal double-strand breaks during replication. In homologous recombination deficiency (HRD) tumors (e.g., BRCA1 or BRCA2 germline or somatic mutations), cancer cells cannot repair double-strand breaks, triggering synthetic lethality and tumor apoptosis while sparing normal cells. Indicated for maintenance therapy in BRCA-mutated advanced ovarian cancer, HER2-negative metastatic breast cancer with germline BRCA mutation, metastatic pancreatic adenocarcinoma, and HRR gene-mutated metastatic castration-resistant prostate cancer.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 300 mg (two 150 mg tablets) twice daily, approximately 12 hours apart with or without food with a full glass of water. Swallow whole; do not chew, crush, or dissolve.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, fatigue, anemia (often requires blood transfusions), vomiting, diarrhea, dysgeusia, neutropenia, thrombocytopenia. Rare/Severe: Myelodysplastic syndrome (MDS) / Acute Myeloid Leukemia (AML in ~1.5% of patients), and pneumonitis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Myelodysplastic syndrome and acute myeloid leukemia (MDS/AML); monitor complete blood count monthly. If severe hematologic toxicity occurs, interrupt therapy until counts recover. Embryofetal toxicity; verified contraception is mandatory.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.